Australia's Invex Therapeutics jumps on collaboration with S.Korea's Peptron

Peptron

27/09/2021 02:36

** Biopharma co Invex Therapeutics  IXC.AX  soars as much as
19.1% to A$0.810 in its biggest intraday percentage rise since
December 2020
    ** Co says https://wcsecure.weblink.com.au/pdf/IXC/02426471.pdf
 signed a long-term collaboration and manufacturing agreement
with South Korean biotech firm Peptron Inc  087010.KQ 
    ** Under the deal, Peptron to give IXC access to its
intellectual property regarding IXC's drug Presendin to treat
neurological conditions
    ** IXC grants Peptron an exclusive licence to commercialise 
Presendin in South Korea for hypertension disorder 
    ** IXC stock hits highest level since March 25
    ** More than 172,000 shares change hands, vs the 30-day
average of about 83,000 shares
    ** IXC down 5% this year, as of last close

 (Reporting by Sameer Manekar in Bengaluru)
 ((Sameer.Manekar@thomsonreuters.com;))